8-K: Aditxt Subsidiary Adimune Completes Preclinical Studies, Advances Towards Human Trials for Autoimmune Therapy

Aditxt's subsidiary, Adimune, has successfully completed preclinical efficacy and safety studies for its ADI-100 immune modulation therapy, paving the way for first-in-human clinical trials.

Summary

• Aditxt's subsidiary, Adimune, has completed preclinical studies for its ADI-100 therapy.
• ADI-100 is designed to restore immune tolerance in autoimmune diseases and for transplanted organs.
• Preclinical studies showed ADI-100 achieved antigen-specific tolerization without impairing the immune system's ability to fight infections or suppress tumor growth.
• In mice models, ADI-100 reversed hyperglycemia in Type 1 Diabetes, restored islet cell mass, and provided durable protection lasting over 300 days.
• Toxicology data confirmed the therapy's safety, with no detectable persistence of plasmids, no formation of anti-plasmid antibodies, and no significant adverse effects.
• Adimune is preparing to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application to initiate first-in-human clinical trials for ADI-100 in the treatment of Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome.
• The autoimmune disease market has a total addressable market (TAM) of $84.12 billion.
• Aditxt plans to introduce two additional programs dedicated to public health and women's health.
• Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. and a Merger Agreement with Evofem Biosciences, Inc. to support these programs.
• The closing of the transactions with Appili and Evofem is subject to several conditions, including Aditxt raising approximately $34 million in cash.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical results for ADI-100 and a clear path towards human trials, indicating strong potential for the company. However, the need for a significant capital raise and the uncertainty of closing the Appili and Evofem transactions temper the overall sentiment slightly.

Positives

• ADI-100 has shown promising results in preclinical studies, demonstrating efficacy in reversing hyperglycemia and restoring islet cell mass in mice with Type 1 Diabetes.
• The therapy has shown no impairment of immune responses to infections or tumor growth in preclinical models.
• ADI-100 has demonstrated a durable protection against hyperglycemia in mice for over 300 days.
• The therapy has a strong safety profile with no detectable persistence of plasmids, no formation of anti-plasmid antibodies, and no significant adverse effects.
• Adimune is positioned to be a front runner in the autoimmune treatment market.
• The company is targeting a large and growing autoimmune disease market with a total addressable market of $84.12 billion.

Negatives

• The closing of the transactions with Appili and Evofem is subject to several conditions, including Aditxt raising approximately $34 million in cash.
• There is no assurance that all conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.
• Failure to secure the required funding could prevent the closing of the merger with Evofem.

Risks

• The company needs to raise a significant amount of capital to fund its obligations at closing for the Appili and Evofem transactions.
• There is a risk that the company may not be able to obtain the necessary funding to commence clinical trials.
• The company faces competition in the autoimmune treatment market.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Adimune is preparing to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application to initiate first-in-human clinical trials for ADI-100 in the treatment of Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome, targeted for H2 2025. Aditxt also plans to introduce two additional programs dedicated to public health and women's health.

Management Comments

• Dr. Friedrich Kapp, Co-CEO of Adimune, stated that the treatment of autoimmune diseases will see a fundamental change in the next few years, with immune tolerance replacing immunosuppressants.
• Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt and Co-CEO of Adimune, said that Adimune represents an opportunity for a fundamental shift in the way we treat autoimmunity.
• Amro Albanna also stated that with the successful completion of ADI-100's preclinical efficacy and safety study, Adimune is closer to bringing this therapy to human trials.

Industry Context

The announcement comes amid increasing industry focus on innovative therapies for autoimmune diseases, highlighted by the recent deal between Roche/Genentech and Cour. Adimune's ADI-100 is positioned as a potential frontrunner in this competitive landscape due to its innovative mechanism of action and strong preclinical data.

Comparison to Industry Standards

• The document mentions a recent deal between Roche/Genentech and Cour on autoimmune treatments, indicating a competitive landscape where safety, effectiveness, and durability of response are key criteria.
• Adimune's ADI-100 is positioned as a frontrunner due to its innovative mechanism of action, broad therapeutic potential, and strong preclinical data, suggesting it aims to meet or exceed industry standards.
• The preclinical results, particularly the durable protection against hyperglycemia in mice for over 300 days, are a positive sign compared to other therapies that may not offer such long-lasting effects.

Stakeholder Impact

• Shareholders may see increased value if ADI-100 progresses successfully through clinical trials.
• Patients with autoimmune diseases may benefit from a new treatment option.
• Employees of Aditxt and Adimune may see increased job security and growth opportunities.
• The company's success could lead to increased collaboration with research institutions and industry partners.

Next Steps

• Adimune will submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application.
• Adimune will initiate first-in-human clinical trials for ADI-100 in the treatment of Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome, targeted for H2 2025.
• Aditxt will seek to close the transactions with Appili and Evofem.
• Aditxt will introduce two additional programs dedicated to public health and women's health.

Key Dates

Keywords

Aditxt, Adimune, ADI-100, autoimmune, gene therapy, clinical trials, preclinical studies, Type 1 Diabetes, Psoriasis, Stiff-Person Syndrome, immune modulation, immunotherapy, Appili Therapeutics, Evofem Biosciences